Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Discover how tirzepatide benefits heart failure in obesity, and see why those with higher BMI may gain even more benefits.

Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...

Trial shows that risk of a major adverse cardiovascular event is eight per cent lower in people on new therapy ...

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, ...

Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...

These results were recently published in Nature Medicine in the study titled "Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial." Subscribe to ...

HealthDay News — For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7% on average, which is lower than the percentages reported ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their prescribed obesity medication, according to findings published in Obesity ...

In clinical practice, injectable glucagon-like peptide-1 (GLP-1) receptor agonists for obesity treatment appear less effective than in clinical trials, largely due to early discontinuation and low ...